Adverse drug reactions associated to the antimalarial chemoprophylaxis;Reacciones adversas asociadas a la quimioprofilaxis antipaludica

Medicina Clinica

Volumn 108, Issue 20, 1997, Pages 772-775

  Corominas, Núria ^a   Gascón, Joaquim ^a   Mejías, Teresa ^a   Caparrós, Francisca ^a   Quintó, Llorenç ^b   Codina, Carles ^a   Ribas, Josep ^a   Corachán, Manuel ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b U de Epidemiologia y Bioestadistica   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; MEFLOQUINE; PROGUANIL;

ADOLESCENT; ADULT; AGED; AMNESIA; ANXIETY; ARTICLE; CHILD; CONVULSION; DEPRESSION; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALARIA; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT ATTITUDE; QUESTIONNAIRE; SIDE EFFECT; TRAVEL; TREMOR; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CHLOROGUANIDE; CHLOROQUINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEFLOQUINE; MIDDLE AGED; QUESTIONNAIRES; TRAVEL;

EID: 0030915987     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Behrens RH, Curtis CF. Malaria in travellers: epidemiology and prevention. Br Med Bull 1993; 49: 363-381.
2. UNDP/World Bank/WHO Update. Development of mefloquine as an antimalarial drug. Bull WHO 1983; 61: 169-178.
3. Steffen R, Fuchs E, Dunlop J, Naef U, Chen D, Stürchler D. Mefloquine: safety and efficacy in european tourists visiting East Africa. Atlanta: Proceedings of the second Conference on International Travel Medicine, 1991.
4. Rouveix B, Bricaire F, Michon C, Franssen G, Lebras J, Bernard J et al. Mefloquine and an acute brain syndrome. Ann Intern Med 1989; 110: 577-578.
5. Stuiver PC, Ligthelm RJ, Goud TJ. Acute psychosis after mefloquine. Lancet 1989; 2: 282.
6. a ed.). Amsterdam: Elsevier Science Publishers, 1988.
7. WHO International Travel and Health. Vaccination requirements and health advice. Ginebra: WHO. 1995.
8. Bem JL, Kerr L, Stuerchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992; 95: 167-179.
9. Bradley DJ, Warhurst DC. Malaria prophylaxis: guidelines for travellers from Britain. Br Med J 1995; 310: 709-714.
10. Kozarsky PH, Eaton M. Use of mefloquine for mslarial chemoprophylaxis in its first year of availability in the United States. Clin Infect Dis 1993; 16: 185-186.
11. Brown GV. Chemoprophylaxis of malaria. Med J Aust 1993; 159: 187-196.
12. Fish DR, Espir MLE. Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy. Br Med J 1988; 297: 526-527.
13. Erickson B, Björkman A, Keisu M. How safe is proguanil? A post-marketing investigation of side-effects. Scand J Infect Dis 1991; 23: 489-493.
14. Steffen R, Heusser R, Mächler R, Bruppacher R, Naef U, Chen D et al. Malaria chemoprophylaxis among european tourists in tropical Africa: use, adverse reactions and efficacy. Bull WHO 1990; 68: 313-322.
15. Phillips Howard PA, Radalowicz J, Mitchell J, Bradley DJ. Risk of malaria in British residents returning from malarious areas. Br Med J 1990; 300: 499-503.
16. Corachan M, Abós R, Añaños G, Navarro P. Información sanitaria de viajeros intercontinentales españoles. Med Clin (Barc) 1990; 94: 92-95.
17. Obrecht O, Bouvet E, Saout C, Perrin J, Andremont A, Kermorvant M. Attitudes towards prevention of communicable diseases among french travellers. Zürich: Proceedings: Conference on International Travel Medicine, 1988.
18. Fogh S, Schapira A, Bygbjerg IC, Jepsen S, Mordhorst CH, Kuijlen K et al. Malaria chemoprophylaxis in travellers to East Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulphadoxine-pyrimethamine Br Med J 1988; 296: 820-822.
19. Gascón J, Pujol A, Codina C, Corachan M. Efectos secundarios del antipalúdico mefloquina. Med Clin (Barc) 1990; 95: 277.
20. Gascón J, Almeda J, Corominas N, Corachan M. Reacción neuropsiquiátrica grave tras la toma de mefloquina. Med Clin (Barc) 1993; 101: 515-516.
21. Pous E, Gascón J, Obach J, Corachán M. Mefloquina-induced grand mal seizure during malaria chemoprophylaxis in a non-epileptic subject. Trans Roy Trop Med Hyg 1995; 89: 434.
22. Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer N et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991; 45: 86-91.
23. Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet 1993; 341: 1.299-1.303.
24. Olson PE, Kennedy CA, Morte PD. Paresthesias and mefloquine prophylaxis. Ann Intern Med 1992; 117: 1.058-1.059.
25. Drysdale SF, Phillips-Howard PA, Behrens RH. Proguanil, chloroquine, and mouth ulcers. Lancet 1990; 335: 164.
26. D'Arcy PF. Mouth ulcers and antimalarials. Int Pharmacy J 1990; 4: 96-97.
27. Scerri L, Pace JL. Mefloquina-associated cutaneous vasculitis. Int J Dermatol 1993; 32: 517-518.
28. Martin GJ, Malone JL, Ross EV. Exfoliative dermatitis during malarial prophylaxis with mefloquine. Clin Infect Dis 1993; 16: 341-342.
29. Van den Enden E, Van Gompel A, Colebunders R, Van den Ende J. Mefloquine-induced Stevens-Johnson syndrome. Lancet 1991; 337: 683.
30. Shlim DR. Severe facial rash associated with mefloquine. JAMA 1991; 266: 2.560.
31. Bernstein HN. Ophtalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med 1983; 75 (Supl 1A): 25-34.
32. Breckenridge A. Risks and benefits of prophylactic antimalarial drugs. Br Med J 1989; 299: 1.057-1.058.